Corporate ActionNov 10, 2026, 05:26 PM
Eupraxia Pharmaceuticals to Sell Up to $300M in Common Shares via Agents Agreement
AI Summary
Eupraxia Pharmaceuticals Inc. has entered into an Open Market Sale Agreement with Jefferies LLC and Jefferies Securities, Inc. to sell up to $300,000,000 of its common shares from time to time. The agreement outlines terms for the sales agents, including a minimum floor price of $1.00 per share. This allows Eupraxia to access capital through the public markets as needed.
Key Highlights
- Eupraxia Pharmaceuticals Inc. entered into an Open Market Sale Agreement with Jefferies LLC and Jefferies Securities, Inc.
- The agreement allows Eupraxia to sell common shares from time to time through the agents.
- The aggregate sales price for the shares is up to $300,000,000.
- The floor price for sales is a minimum of $1.00 per share, adjustable by the company.
- The agreement is effective from November 10, 2026, and remains active until terminated.
Price Impact
More from EPRX
Corporate Action1d ago, 4:22 PM
Eupraxia Pharmaceuticals Establishes $125M At-The-Market Offering Program
Quarterly Result1d ago, 4:02 PM
Eupraxia Pharmaceuticals Reaches EoE Trial Enrollment; Q3 Loss $15.2M
Clinical TrialOct 9, 8:36 AM
Eupraxia Pharmaceuticals to Present EoE Trial Data at ACG and UEG Conferences